CCR5-based stem cell gene therapy: Hope for HIV infection cure
Journal of Antivirals & Antiretrovirals

Journal of Antivirals & Antiretrovirals
Open Access

ISSN: 1948-5964

CCR5-based stem cell gene therapy: Hope for HIV infection cure

International Conference and Exhibition on VIROLOGY

5-7 September 2011 Baltimore, USA

Kai Li

Scientific Tracks Abstracts: JAA

Abstract :

In 2011, Allers et al.?s reported a cure of patient with HIV infection (1). Results showing that a patient remained without HIV infection for more than 3.5 years aft er accepting CCR5-_32 bone marrow transplant supported the therapeutic potential of CCR5-_32 related gene therapy strategies. Among HIV-related cellular targets, CCR5 appears to be the focus of gene therapy related studies (2). Two types of particular clinical epidemiological observations prompted us to think the possibility of CCR5-based hematopoietic stem cell gene therapy against HIV infection. Th e fi rst evidence is the identifi cation of mutant CCR5 having resistant to HIV infection by three independent reports in 1996 (3-5). Another brainstorming data were that anti-CCR5 IgA had been confi rmed for its protective eff ect against HIV infection (6). As our body chosen CCR5 to be a target of immune system in respecting to preventing from HIV infection, the anti-CCR5 IgA may suggest the diffi culties in the development of vaccine directly targeting HIV itself. As early as 2005, we described these HIV gene therapy strategies as follows: In a therapeutic point of view AIDS can be treated as aplastic anemia or leukemia and transplanted with bone marrow carrying CCR5-_32. ?However, allogenic bone marrow transplantation has two drawbacks: immune rejection and the limited number of available donors. ? Th us, in order to be more benefi cial to more HIV infected people, it is technically easier to introduce the CCR5-_32 genotype through genetic engineering of hemopoietic stem cells isolated from the patients themselves (7) Although it is still too early for defi nitive conclusions on the therapeutic potential of CCR5-based stem cell gene therapy strategies, it is our hope that more individuals with HIV infection will benefi t from these new therapeutic strategies.